Abstract
To evaluate the era of direct acting antivirals (DAAs), we must understand the treatment patterns and outcomes of interferon-based therapy for hepatitis C virus (HCV) infection. We aimed to elucidate the treatment rate, factors affecting treatment decisions, and efficacy of interferon- based therapy in a real-world setting. This nationwide cohort study included 1,191 newly diagnosed patients with chronic HCV infection at seven tertiary hospitals in South Korea. Subjects were followed retrospectively until March 2015, which was just before the approval of DAA therapy. In total, 48.2% and 49.3% of the patients had HCV genotypes 1 and 2, respectively. Interferon-based therapy was initiated in 541 patients (45.4%). The major reasons for no treatment included ineligibility (18.9%), concern about adverse events (22.3%), cost (21.5%), and an age >75 years (19.5%). Interferon-based therapy was discontinued (18.5%) mainly due to adverse events (n=66). The intent-to-treat analysis found that the sustained virologic response (SVR) rate was 58.3% in genotype 1 patients and 74.7% in nongenotype 1 patients. Approximately one-third of newly diagnosed HCV patients in South Korea received interferon-based therapy and showed a suboptimal SVR rat...Continue Reading
References
Sep 27, 2002·The New England Journal of Medicine·Michael W FriedJian Yu
Mar 5, 2004·Annals of Internal Medicine·Stephanos J HadziyannisUNKNOWN PEGASYS International Study Group
Feb 27, 2008·Alimentary Pharmacology & Therapeutics·G BorroniF Salerno
Jun 10, 2008·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Peter JepsenHenrik Toft Sørensen
Sep 13, 2011·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·Kwangsoo LyooSeung Kew Yoon
Apr 19, 2012·The Korean Journal of Hepatology·Ki Tae SukUNKNOWN Korean Association for the Study of the Liver
Nov 23, 2012·The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi·Soo Yong ParkJu Hyun Kim
Nov 23, 2012·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Khayriyyah Mohd HanafiahSteven T Wiersma
Jan 8, 2013·Alimentary Pharmacology & Therapeutics·A H TalalE J Korner
Jan 17, 2013·Clinical and Molecular Hepatology·Seok Hoo JeongJu Hyun Kim
Feb 28, 2013·Journal of Clinical Gastroenterology·Young Kul JungKwan Soo Byun
Apr 18, 2013·Clinical and Molecular Hepatology·Young Kul Jung, Ju Hyun Kim
May 8, 2013·Journal of Viral Hepatitis·A S Rangnekar, R J Fontana
Apr 10, 2014·Journal of Viral Hepatitis·H WedemeyerE Gower
Nov 8, 2014·Digestive Diseases·Jeong Min LeeByung Ihn Choi
Apr 4, 2015·Medicine·Ming-Lung YuWen-Yu Chang
Jul 15, 2015·PloS One·Adi V GundlapalliJoanne LaFleur
Jul 28, 2015·Journal of Medical Virology·Sang Soo LeeHan Chu Lee
Feb 10, 2016·Journal of Viral Hepatitis·L HawksA D Fox
Apr 6, 2016·Clinical and Molecular Hepatology·UNKNOWN Korean Association for the Study of the Liver
Jul 11, 2016·Lancet·Jeffrey D StanawayGraham S Cooke
Citations
Aug 5, 2017·Epidemiology and Health·Sook-Hyang JeongMoran Ki
Jul 13, 2018·Liver International : Official Journal of the International Association for the Study of the Liver·Kyung-Ah KimSook-Hyang Jeong
Nov 22, 2018·Journal of Gastroenterology and Hepatology·Wankyo ChungSook-Hyang Jeong
Aug 23, 2019·Hepatology International·Eun Sun JangUNKNOWN Korean hepatitis epidemiology study group
Aug 17, 2019·Eye and Vision·Ghada Al BayyatCarol L Karp
Dec 5, 2017·Euroasian Journal of Hepato-gastroenterology·Stella C PakUmar Darr